These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9214398

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O, Feldman J, Friedman EA.
    N Engl J Med; 1996 Feb 15; 334(7):420-5. PubMed ID: 8552143
    [Abstract] [Full Text] [Related]

  • 3. Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s?
    Ifudu O, Mayers JD, Matthew JJ, Macey LJ, Brezsnyak W, Reydel C, McClendon E, Surgrue T, Rao TK, Friedman EA.
    Am J Kidney Dis; 1997 Apr 15; 29(4):549-52. PubMed ID: 9100043
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus infection and the response to erythropoietin in end-stage renal disease.
    Ifudu O, Fowler A.
    ASAIO J; 2001 Apr 15; 47(5):569-72. PubMed ID: 11575840
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, End-Stage Renal Disease Core Indicators Work Group.
    Am J Kidney Dis; 2001 May 15; 37(5):E36. PubMed ID: 11325701
    [Abstract] [Full Text] [Related]

  • 7. Trends in anemia management among US hemodialysis patients.
    Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF.
    J Am Soc Nephrol; 2002 May 15; 13(5):1288-95. PubMed ID: 11961017
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D, Rao TK, Sinert R, Khurana E, Lundin AP, Friedman EA.
    Am J Kidney Dis; 1995 Jun 15; 25(6):904-9. PubMed ID: 7771487
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C, Carrera F, Jorge C, Boquinhas H, Pais MJ.
    Nephrol Dial Transplant; 2006 Nov 15; 21(11):3202-6. PubMed ID: 16891651
    [Abstract] [Full Text] [Related]

  • 13. Gender modulates responsiveness to recombinant erythropoietin.
    Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA.
    Am J Kidney Dis; 2001 Sep 15; 38(3):518-22. PubMed ID: 11532683
    [Abstract] [Full Text] [Related]

  • 14. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF, Szczech L, Johnson C, Frankenfield D.
    Am J Kidney Dis; 1999 Oct 15; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS.
    Am J Health Syst Pharm; 1998 Dec 15; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F, Aracil FJ, Pérez R, Valderrábano F.
    Am J Kidney Dis; 1996 Apr 15; 27(4):548-56. PubMed ID: 8678066
    [Abstract] [Full Text] [Related]

  • 19. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
    Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS.
    Am J Nephrol; 1998 Apr 15; 18(6):498-503. PubMed ID: 9845824
    [Abstract] [Full Text] [Related]

  • 20. Predictors of erythropoietin responsiveness in chronic hemodialysis patients.
    Tonelli M, Blake PG, Muirhead N.
    ASAIO J; 2001 Apr 15; 47(1):82-5. PubMed ID: 11199321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.